In the first quarter of 2025, Dutch startups raised just $503mn (€429mn), the lowest since the early pandemic. However, total funding for H1 reached $1.4bn (€1.2bn), down from $1.8bn (€1.54bn) in 2024 but up from H1 2023's $1.1bn (€940mn). The second quarter notably improved, with a funding surge of $856mn (€940mn). The biotech sector led this momentum, accounting for half of the top ten funding rounds. Significant amounts were raised by startups such as Azafaros and Finom, indicating growth potential in specific fields.
In the first quarter of this year, startups in the Netherlands raised just $503mn (€429mn), marking the lowest quarterly total since early COVID-19 days.
Total funding for H1 2025 hit $1.4bn (€1.2bn), a decline from $1.8bn (€1.54bn) last year, yet higher than H1 2023's $1.1bn (€940mn).
The second quarter saw a significant rebound, with startups securing $856mn (€940mn), highlighting a 70% increase from Q1.
Biotech leads the funding momentum, with half of the top 10 funding rounds in H1 coming from life sciences startups.
Collection
[
|
...
]